UNSPSC 51142544: Apomorphine hydrochloride anhydrous

This classification denotes a dopamine agonist and antiparkinsonian agent C17H17NO2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9K13MD7A0D, chemically known as (6ar)-5,6,6a,7-tetrahydro-6-methyl-4h-dibenzo(de,g)quinoline-10,11-diol hydrochloride, but more generally known as apomorphine hydrochloride anhydrous, which bears US NIH Compound Identifier 9410. Most nations, for tariff and trade purposes, schedule apomorphine hydrochloride anhydrous under HS 29391900 and SITC 54141.

As of Q4 2014, APOMORPHINE HYDROCHLORIDE ANHYDROUS remains US FDA's Preferred Term for this commodity. Apomorphine hydrochloride anhydrous bears US NLM identifiers UMLS ID C0887720 and NCI Concept Code C80572. SMILES: CN1CCC2CCCC-3C2[C@H]1CC4C3C(C(CC4)O)O.CL.

UNSPSC 51142544 Apomorphine hydrochloride anhydrous is a Commodity code that in practice covers pharmaceutical products procured by state and local health agencies, though recent state and local solicitations tagged to this code span a broader pharmaceutical and pharmacy-benefit portfolio. State and local governments use this code to buy generic pharmaceuticals, naloxone products, and over-the-counter medications for public health programs, substance-abuse response initiatives, and employee health benefit programs. Issuing bodies include state health departments (such as the Texas Health and Human Services Commission), county health agencies (such as Seminole County, Florida), and cooperative purchasing alliances (such as the Minnesota Multistate Cooperative Purchasing Alliance) that aggregate demand across multiple jurisdictions and member states. The work solicited ranges from direct purchase of naloxone and drug-deactivation systems for community health distribution, to wholesale supply agreements for generic pharmaceutical lines through authorized pharmaceutical wholesalers, to direct-to-manufacturer contracting models that bypass traditional pharmacy benefit managers and group purchasing organizations.

Recent activity spans Florida, Texas, and Minnesota, with multistate reach through cooperative vehicles. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking annual procurement of 1,900 units of naloxone and 800 safe drug-deactivation systems with quarterly delivery to its Community Health Building in Sanford, with a response deadline of July 26, 2023 (note: date inconsistency in source). The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to gather vendor capabilities for implementing a direct-to-manufacturer pharmaceutical prescription program outside traditional pharmacy benefit manager channels. The Minnesota Department of Administration issued RFP S1070000015802 through the MMCAP cooperative in January 2026 for generic multi-source pharmaceuticals and OTC products to be distributed through authorized wholesalers to state and local government facilities across participating states including Oregon, with proposals due March 26, 2026 and contract effectiveness July 1, 2026. All three solicitations require vendors to meet FDA and drug supply-chain compliance standards, maintain specified insurance coverage, and submit detailed product and pricing documentation.